Literature DB >> 21225914

Isocitrate dehydrogenase 1/2 mutational analyses and 2-hydroxyglutarate measurements in Wilms tumors.

Dinesh Rakheja1, Midori Mitui, Richard L Boriack, Ralph J DeBerardinis.   

Abstract

BACKGROUND: L-2-Hydroxyglutaric aciduria (L-2-HGA) is an uncommon inborn error of metabolism, in which the patients are predisposed to develop brain tumors. Elevated levels of D-2-hydroxyglutarate have been demonstrated with malignant gliomas and myeloid leukemias associated with somatic mutations of the genes encoding NADP(+)-dependent isocitrate dehydrogenases (IDH1 and IDH2, respectively). Recently, we noted a Wilms tumor in a child with L-2-HGA. Given the accumulating evidence that both enantiomers of 2-hydroxyglutarate are associated with cellular transformation, we investigated if sporadic Wilms tumors are associated with IDH1 or IDH2 mutations or with elevated levels of 2-hydroxyglutarate. PROCEDURE: We retrieved 21 frozen Wilms tumor tissues. In 20 cases, we sequenced exon 4 and flanking intronic regions of IDH1 and IDH2. In all 21 cases, we measured 2-hydroxyglutarate levels by liquid chromatography-tandem mass spectrometry.
RESULTS: We did not find mutations at the hot spots IDH1 codon 132 or IDH2 codon 172. Two cases (1 with favorable histology and 1 with unfavorable histology) showed heterozygous change c.211G>A (p.Val71Ile) in IDH1, a change previously reported as a mutation but listed as a single nucleotide polymorphism in the NCBI SNP database. We did not find increased levels of 2-hydroxygluatric acid in any sample.
CONCLUSIONS: Our results suggest that IDH1 codon 132 or IDH2 codon 172 mutations or elevated 2-hydroxyglutarate levels do not play a role in the biology of sporadic Wilms tumors. The significance of heterozygous change c.211G>A (p.Val71Ile) in IDH1, seen in two tumors, is not clear.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21225914     DOI: 10.1002/pbc.22697

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.838


  13 in total

1.  Oxidation of alpha-ketoglutarate is required for reductive carboxylation in cancer cells with mitochondrial defects.

Authors:  Andrew R Mullen; Zeping Hu; Xiaolei Shi; Lei Jiang; Lindsey K Boroughs; Zoltan Kovacs; Richard Boriack; Dinesh Rakheja; Lucas B Sullivan; W Marston Linehan; Navdeep S Chandel; Ralph J DeBerardinis
Journal:  Cell Rep       Date:  2014-05-22       Impact factor: 9.423

2.  Quantitative metabolic flux analysis reveals an unconventional pathway of fatty acid synthesis in cancer cells deficient for the mitochondrial citrate transport protein.

Authors:  Lei Jiang; Adam Boufersaoui; Chendong Yang; Bookyung Ko; Dinesh Rakheja; Gerardo Guevara; Zeping Hu; Ralph J DeBerardinis
Journal:  Metab Eng       Date:  2016-11-14       Impact factor: 9.783

3.  Ascorbic acid-induced TET activation mitigates adverse hydroxymethylcytosine loss in renal cell carcinoma.

Authors:  Niraj Shenoy; Tushar D Bhagat; John Cheville; Christine Lohse; Sanchari Bhattacharyya; Alexander Tischer; Venkata Machha; Shanisha Gordon-Mitchell; Gaurav Choudhary; Li-Fan Wong; LouAnn Gross; Emily Ressigue; Bradley Leibovich; Stephen A Boorjian; Ulrich Steidl; Xiaosheng Wu; Kith Pradhan; Benjamin Gartrell; Beamon Agarwal; Lance Pagliaro; Masako Suzuki; John M Greally; Dinesh Rakheja; R Houston Thompson; Katalin Susztak; Thomas Witzig; Yiyu Zou; Amit Verma
Journal:  J Clin Invest       Date:  2019-03-04       Impact factor: 14.808

4.  2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas.

Authors:  Changho Choi; Sandeep K Ganji; Ralph J DeBerardinis; Kimmo J Hatanpaa; Dinesh Rakheja; Zoltan Kovacs; Xiao-Li Yang; Tomoyuki Mashimo; Jack M Raisanen; Isaac Marin-Valencia; Juan M Pascual; Christopher J Madden; Bruce E Mickey; Craig R Malloy; Robert M Bachoo; Elizabeth A Maher
Journal:  Nat Med       Date:  2012-01-26       Impact factor: 53.440

Review 5.  Progress in understanding 2-hydroxyglutaric acidurias.

Authors:  Martijn Kranendijk; Eduard A Struys; Gajja S Salomons; Marjo S Van der Knaap; Cornelis Jakobs
Journal:  J Inherit Metab Dis       Date:  2012-03-06       Impact factor: 4.982

6.  Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production.

Authors:  P S Ward; J R Cross; C Lu; O Weigert; O Abel-Wahab; R L Levine; D M Weinstock; K A Sharp; C B Thompson
Journal:  Oncogene       Date:  2011-09-26       Impact factor: 8.756

7.  IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors.

Authors:  Marta Mellai; Angela Piazzi; Valentina Caldera; Oriana Monzeglio; Paola Cassoni; Guido Valente; Davide Schiffer
Journal:  J Neurooncol       Date:  2011-06-04       Impact factor: 4.506

8.  The emerging role of d-2-hydroxyglutarate as an oncometabolite in hematolymphoid and central nervous system neoplasms.

Authors:  Dinesh Rakheja; L Jeffrey Medeiros; Scott Bevan; Weina Chen
Journal:  Front Oncol       Date:  2013-07-02       Impact factor: 6.244

9.  Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromes.

Authors:  Peipei Lin; Yingwan Luo; Shuanghong Zhu; Dominic Maggio; Haiyang Yang; Chao Hu; Jinghan Wang; Hua Zhang; Yanling Ren; Xinping Zhou; Chen Mei; Liya Ma; Weilai Xu; Li Ye; Zhengping Zhuang; Jie Jin; Hongyan Tong
Journal:  J Cancer Res Clin Oncol       Date:  2018-03-16       Impact factor: 4.322

10.  D2HGDH regulates alpha-ketoglutarate levels and dioxygenase function by modulating IDH2.

Authors:  An-Ping Lin; Saman Abbas; Sang-Woo Kim; Manoela Ortega; Hakim Bouamar; Yissela Escobedo; Prakash Varadarajan; Yuejuan Qin; Jessica Sudderth; Eduard Schulz; Alexander Deutsch; Sumitra Mohan; Peter Ulz; Peter Neumeister; Dinesh Rakheja; Xiaoli Gao; Andrew Hinck; Susan T Weintraub; Ralph J DeBerardinis; Heinz Sill; Patricia L M Dahia; Ricardo C T Aguiar
Journal:  Nat Commun       Date:  2015-07-16       Impact factor: 17.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.